Consortium Members

Logo University of Oxford

University of Oxford (United Kingdom)

Principal investigators: Prof. David L. H. Bennett (Project Co-ordinator) and Prof. Mark McCarthy

The University of Oxford will act as co-ordinator of DOLORisk. The university and linked hospitals have experience in clinical phenotyping of diabetes, neuropathy and neuropathic pain receiving both regional and national referrals to the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) and the Nuffield Department of Clinical Neuroscience (NDCN). This will facilitate patient recruitment (WP1) and assessment (WPs 4-5-6). The Wellcome Trust Centre for Human Genetics is a world leading centre for genomics with all necessary infra-structure for sequencing and bioinformatic analysis proposed in WP2. NDCN has a critical mass of pain biologists with techniques ranging from cellular electrophysiology to transcriptional profiling to be used in (WP3).

Questions on the project can be submitted through the contact form.

Logo Imperial College

Imperial College London (United Kingdom)

Principal investigator: Prof. Andrew S. C. Rice

Imperial College will participate in DOLORisk: Through the Pain Research Group headed by Professor Andrew Rice (Department of Surgery and Cancer, Faculty of Medicine), Imperial and the linked Chelsea and Westminster Hospital NHS Foundation Trust, have extensive expertise in the key scientific and clinical domains to successfully deliver this work programme. These include clinical profiling and patient stratification of peripheral neuropathy and neuropathic pain. The clinical pain management service is one of the largest specialised pain clinics in London. The clinical group has a track record of strong local collaboration with the diabetes unit for clinical research. Chelsea and Westminster is an accredited Advanced Pain Training centre and has been awarded the German Neuropathic Pain Network quality standard for Quantitative Sensory Testing. The group have a track record in phenotyping studies and have successfully collaborated with most of the other DOLORisk participants on multi-centre projects, notably the Oxford group for diabetic neuropathy in the PiNS (Pain in Neuropathy study) and within the NEUROPAIN network led from Kiel.

Logo University of Dundee

University of Dundee (United Kingdom)

Principal investigators: Prof. Blair H. Smith, Prof. Colin Palmer and Dr. Weihua Meng

The University of Dundee will lead WP7, Developing a Risk Model for Neuropathic Pain. At Dundee, the Medical Research Institute specializes in harnessing large, high quality clinical datasets for answering important questions, particularly in metabolic and neurological diseases. It includes the internationally-renowned Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics (Palmer) and the Chronic Pain Research Group (Smith). The Health Informatics Centre has pioneered and developed sophisticated bioinformatics facilities, including collection and management of high quality data for research, with versatile linkage between research-derived and routine health records. Recent significant investment places Dundee at the forefront of Health Informatics in the UK and internationally. Population health science research is supported by the Dundee Epidemiology and Biostatistics Unit. Smith and Palmer will work with Dr Weihua Meng (lecturer in genetic epidemiology), Dr Harry Hebert (research assistant in genetic epidemiology) and PhD student Abirami Veluchamy trained in epidemiology and statistics.

Logo Mentis Cura

Mentis Cura (Iceland)

Principal investigator: Dr. Kristinn Johnsen

MentisCura Diagnostics (MC), based in Reykjavik, Iceland, is an SME specialized in electrophysiological biomarkers for central nervous system (CNS) disorders. MC’s products and services help improve and accelerate CNS drug development, and provide clinical diagnostic support for dementia and ADHD. MC has built an extensive EEG database and expertise in electroencephalogram (EEG)-based classification algorithms for brain disorders. MC will apply the same methodology to analyze EEG in patients with or at risk of developing neuropathic pain (WP5).


INSERM - Institut National de la Sante et de la Recherche Medicale (France)

Principal investigators: Dr Didier Bouhassira and Prof. Nadine Attal

The UMR 987 entitled «Pathophysiology and Clinical Pharmacology of Pain » associated with Inserm and UVSQ is a ‘mono thematic’ and ‘mono-équipe’ unit hosted by Assistance Publique Hôpitaux de Paris (AP-HP) in Ambroise Paré University Hospital in Boulogne-Billancourt (Paris Ile de France West Medical Faculty). Its research activities are exclusively devoted to clinical research and include studies both in patients with various types of acute (postoperative) or chronic pain syndromes and in heathy volunteers. This unit has a large experience in the validation and development of clinical tools specific for neuropathic pain including DN4 for screening, that allowed the largest epidemiological study of the prevalence of pain with neuropathic characteristics in Europe, and Neuropathic Pain Symptom Inventory (NPSI) for assessment, which is largely used in large scale pharmacological trials: both tools will be used in the present project (WP1 and 4). This unit also has a longstanding experience of sensory analysis of neuropathic pain including particularly quantitative sensory testing. Our unit also has contributed to implement a mechanism based classification of neuropathic pain, using a multimodal approach of patients with neuropathic pain. Finally this unit has expertise in the prediction and risk factors of chronic pain based on large cohorts of surgical or oncology patients who will be used for the present project.

Logo Kiel University

Christian-Albrechts-Universität zu Kiel (Germany)

Principal investigators: Prof. Dr. med. Ralf Baron and Dr. Janne Gierthmühlen

The University of Kiel (CAU) has experience in clinical phenotyping of neuropathic pain patients receiving both regional and national referrals. At the university hospital outpatients and inpatients are treated in a multidisciplinary way. Furthermore, the Division of Neurological Pain Research and Therapy is affiliated to the Department of Neurology and has access to patients with polyneuropathy of all etiologies. This will facilitate patient recruitment and assessment (WP 1 and 4).

Logo Lund University

Lund University (Sweden)

Principal investigator: Prof. Leif Groop

The participants from Lund University are all members of the Lund University Diabetes Centre (LUDC), a Centre of Excellence funded in 2006 by the Swedish Research Council and one of the leading diabetes centres in the world. They are located at the Clinical Research Centre of the University, Malmö University Hospital, which is closely connected to the Clinic of Diabetes and Endocrinology, creating the ideal setting for both basic and clinical research. LUDC combines the university’s expertise on endocrinology, diabetes genetics, pancreatic Beta-cells, inflammation and (cardio)vascular complications, with diabetes type 1 and 2 as central points of interest. Our research interests include the genetics of diabetes and the metabolic syndrome, diabetes patient stratification, gene-environment interactions, candidate gene screening, epigenetic modifications, tissue-specific gene expression.

Logo Technion

Technion Israel Institute of Technology (Israel)

Principal investigators: Prof. David Yarnitsky and Dr. Yelena Granovksy

Technion is Israel's oldest University, located on Mount Carmel, in Haifa, and focused on technology. It takes pride in 3 Nobel laureates among its staff, two of them are from the faculty of Medicine. The faculty of medicine has 6 general hospitals as its teaching facility, with Rambam as the largest one, carrying the larger part of teaching. Rambam has nearly 1000 beds, serves as the tertiary referral centre for northern Israel, and carries all medical and surgical subspecialties. Dedicated research units exist in both Technion and the hospital, supporting all logistic and financial work related to research performance. Specifically, the department of Neurology and the Clinical Neurophysiology lab, both headed by Prof Yarnitsky, are very well experienced in performance of clinical trial protocols, having the professional staff and the equipment for smooth performance of such studies. For the purpose of this study – the department operates one of the country's largest EMG institutes, whose team is exposed to very large numbers of neuropathy patients. Further, hospital's Oncology facility for northern Israel treats large number of patients receiving chemotherapy, for longitudinal study on development of neuropathy. In addition, large volume surgical activity ensures access to post-surgical pain patients, and cooperation with surgical departments on issues of post-operative pain had already been exercised (and published).

Logo Ghent University

Universiteit Gent (Belgium)

Principal investigator: Prof. Geert Crombez

Today Ghent University attracts over 41,000 students, with a foreign student population of about 4,000. In 2013, the university invested about 265 million Euros in research projects on behalf of public and private partners, and appointed about 5,800 scientific staff members. Ghent University is the only Belgian university in the top 100 of both the Shanghai (85) and Times ranking (85). The university provides excellent training opportunities to both young and experienced researchers, and awarded around 553 PhD degrees in 2013 of which over 20% went to international young researchers. The university is one of the fastest growing European universities in terms of research capacity and productivity.

The “Ghent Health Psychology Lab” is part of the Faculty of Psychology and Educational Sciences of Ghent University, and consists of 3 tenured positions (G. Crombez, S. Van Damme & L. Goubert) and 1 tenure track position (Tine Vervoort), 3 postdoctoral researchers and 16 PhD students. The Lab creates innovative fundamental and translational research about the psychology of pain. The research is grounded in a biopsychosocial perspective allowing research at different levels of analysis, and allowing a swift translation to applied settings. The lab will bring in its internationally acknowledged expertise relating to the role of cognitive, affective, motivational and lifestyle variables in the development and exacerbation of pain, distress and disability (WP6). Additionally, research will be focused upon the interaction between biological and psychological variables within a diathesis-stress model.

Logo Neuroscience Technologies

Neuroscience Technologies (Spain)

Principal investigator: Dr. Jordi Serra

Neuroscience Technologies is a biomedical company with expertise in human pain neurophysiology that helps the pharmaceutical and biotechnology industries in assessing their new analgesic compounds with the use of objective biomarkers of spontaneous pain. Founded in 2005, Neuroscience Technologies is based in Barcelona and opened a subsidiary in London in 2011, where it offers clinical human studies. Neuroscience Technologies is the only SME of Europain, a project funded by the IMI JU since 2009. NT has fully equipped animal and human laboratories comprising: electromyography and nerve conduction studies, somatosensory evoked potentials, Quantitative sensory testing, thermography and microneurography. Neuroscience Technologies will use in vivo electrophysiology of peripheral nerves to produce objective measures of spontaneous and evoked pain, as well as to obtain multiple measures of nerve excitability. These methods will allow the study of responses to suprathreshold stimuli, the assessment of ongoing activity in peripheral nociceptors, and the underlying mechanisms of membrane hyperexcitability in FMS patients. In particular, NT will be involved in WP1, phenotyping patients that will be used for nerve excitability studies, and in WP5, obtaining objective measures of peripheral nerve excitability that quantify the function of different ion channels and pumps in peripheral neuropathic pain patents.

Logo Aarhus University

Aarhus Universitet (Denmark)

Principal investigator: Prof. Nanna Finnerup

Aarhus Universitet will be working within WP 4, 5, and 6 with sensory profiling, physiological measures and psychosocial risk factors of patients with neuropathic pain and will take part in prospective studies, particular patients undergoing surgery and chemotherapy and collect data for WP 27 and 8. The participant is also part of the IMI consortia Europain.

Logo Aarhus University Hospital

Aarhus Universitetshospital (Denmark)

Principal investigator: Prof. Troels S. Jensen

Aarhus University Hospital will be working within WP 4, 5, and 6 with sensory profiling, physiological measures and psychosocial risk factors of patients with neuropathic pain and will take part in prospective studies, particular patients undergoing surgery and chemotherapy and collect data for WP 27 and 8. The participant is also part of the IMI consortia Europain.